This article is more than 5 years old. Information may no longer be current.

Integra announces controlled market release of expandable system

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Integra LifeSciences Holdings Corporation recently announced the controlled U.S. market release of its Expandable Interbody System.

Earlier this year, the system received 510(k) clearance from the U.S. Food and Drug Administration. It is intended for spinal fusion procedures at one or two contiguous levels (L2-S1) in skeletally mature patients with degenerative disc disease, according to a company press release.

Integra’s Expandable Interbody System is designed to minimize the amount of implant insertion forces while helping the surgeon to achieve the patient-specific anatomical fit needed for proper treatment, according to the release. The use of a mechanical mechanism allows for 50% expansion from the system’s original starting height while maintaining a consistent graft aperture.

The system is intended for use with autogenous bone graft and supplemental fixation, and it is appropriate for use in posterior or transforaminal lumbar interbody fusion procedures, according to the release.

Reference: www.integralife.com.